Stay updated on Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial

Sign up to get notified when there's something new on the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The site footer revision changed from v3.7.0 to v3.7.1.
    Difference
    0.2%
    Check dated 2026-10-12T08:13:26.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    No Change Detected
  4. Check
    23 days ago
    Change Detected
    Summary
    The study record page now displays a 403 Forbidden error, replacing the previous detailed content. The detailed study information and related navigation are effectively hidden behind an access-block page.
    Difference
    16%
    Check dated 2026-09-21T08:34:55.000Z thumbnail image
  5. Check
    30 days ago
    Change Detected
    Summary
    The website_changes section shows no additions or deletions, indicating the page content remains the same according to the supplied data.
    Difference
    0.0%
    Check dated 2026-09-14T08:22:19.000Z thumbnail image
  6. Check
    37 days ago
    Change Detected
    Summary
    A new study site was added in Sfax, Tunisia (1053), expanding enrollment options. The prior Tunisia site entry (1053) was removed.
    Difference
    0.4%
    Check dated 2026-09-07T08:37:40.000Z thumbnail image
  7. Check
    44 days ago
    Change Detected
    Summary
    The page adds two NIH grant entries (2018 and 2023) and updates the revision to v3.6.6, while the previous revision v3.6.5 is removed.
    Difference
    0.1%
    Check dated 2026-08-31T07:29:24.000Z thumbnail image
  8. Check
    65 days ago
    Change Detected
    Summary
    The study record now lists LEO Pharma as sponsor and includes key personnel roles along with a revision tag (Revision: v3.6.5) to reflect the latest data; deletions remove older Boehringer Ingelheim data-sharing policy text and related IPD plan details from the page.
    Difference
    0.8%
    Check dated 2026-08-10T09:55:14.000Z thumbnail image

Stay in the know with updates to Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Spesolimab Long-Term in Generalized Pustular Psoriasis Clinical Trial page.